NovaBridge Biosciences (NBP) Common Equity (2017 - 2025)

NovaBridge Biosciences (NBP) has 9 years of Common Equity data on file, last reported at $230.9 million in Q4 2025.

• Common Equity for Q4 2025 came in at $230.9 million, up 14.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $230.9 million (up 14.8% YoY), and the FY2025 annual result was $230.9 million, up 14.8% from the prior year.
• Common Equity fell to $230.9 million in Q4 2025 per NBP's latest filing, from $258.9 million in the prior quarter.
• Over five years, Common Equity peaked at $713.2 million in Q4 2021 and troughed at $196.7 million in Q2 2025.
• A 5-year average of $356.0 million and a median of $248.8 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity plunged 42.63% in 2022, then grew 14.8% in 2025.
• A 5-year view of Common Equity shows it stood at $713.2 million in 2021, then sank by 42.63% to $409.1 million in 2022, then plunged by 41.68% to $238.6 million in 2023, then declined by 15.7% to $201.2 million in 2024, then advanced by 14.8% to $230.9 million in 2025.
• Business Quant data shows NBP's Common Equity at $230.9 million in Q4 2025, $258.9 million in Q3 2025, and $196.7 million in Q2 2025.